Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary? - Summary - MDSpire

Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?

  • By

  • Conrad Leitsmann

  • Alexander Stephan Reese

  • Richard Zigeuner

  • Hanna Zurl

  • Klara Pohl

  • Johannes Mischinger

  • Iva Simunovic

  • Carl Ketterer

  • Florestan Koll

  • Sebastian Mannweiler

  • Marianne Leitsmann

  • Sascha Ahyai

  • June 12, 2026

  • 0 min

Share

Objective:

To evaluate the rate of malignancy in patients undergoing elective TURBT for suspected bladder cancer (BC) specifically.

Key Findings:
  • 35% of patients had no malignancy in the TURBT specimen (95% CI: [X, Y]).
  • Interobserver congruence was observed in 80.6% of cases (p < 0.001).
  • Significant predictors for malignancy included papillary findings (OR = 5.6, 95% CI: [X, Y]), age (OR = 1.057, 95% CI: [X, Y]), interobserver congruence (OR = 99.3, 95% CI: [X, Y]), and tumor size (OR = 1.9, 95% CI: [X, Y]).
Interpretation:

Direct TURBT may not be obligatory for all patients with suspicious bladder lesions, suggesting a need for improved preoperative diagnostic strategies.

Limitations:
  • The study is retrospective and conducted at a single center, which may limit generalizability.
  • Potential biases in patient selection and data collection may affect results.
  • The short timeframe of the study may not capture long-term trends.
Conclusion:

There is a need to establish more selective criteria for TURBT to avoid unnecessary procedures, which could inform future research directions.

Original Source(s)

Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?

  • by Conrad Leitsmann, Alexander Stephan Reese, Richard Zigeuner, Hanna Zurl, Klara Pohl, Johannes Mischinger, Iva Simunovic, Carl Ketterer, Florestan Koll, Sebastian Mannweiler, Marianne Leitsmann, Sascha Ahyai

  • June 12, 2026

Related Content

I’ve spent 40 years in research. I have never seen a threat to science like the new grantmaking rule

Case Report: Decade-delayed thyroid metastasis with cervical lymph node involvement from clear cell renal cell carcinoma: diagnostic pitfalls of cytologic-radiologic discordance

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease